ABSTRACT: Daytime sleepiness, impaired cognitive performance and dysphoric mood are often present in patients with obstructive sleep apnoea syndrome (SAS). This prospective controlled study evaluates the effects of treatment with continuous positive airway pressure (CPAP) during 1 yr on daytime functioning in a large group of patients with SAS.

Patients with sleep apnoea syndrome (SAS) often complain of several deficits in neuropsychological performance at consultation. For instance, daytime sleepiness is a hallmark of the disease. Furthermore, dysphoric mood and abnormal cognitive performance are not uncommon in these patients [1–6]. Finally, NAEGELE et al. [7] showed in a controlled study that patients with SAS often present memory deficits and frontal lobe related abnormalities.

Clinical experience has shown that the use of nasal continuous positive airway pressure (CPAP) in patients with SAS is very effective in improving these symptoms. However, previous studies aimed at objectively assessing these effects were often uncontrolled [8, 9], included a small number of patients and/or were of short duration [10–17]. This had lead some authors to question the usefulness of CPAP treatment in patients with SAS [18].

To provide firm evidence on the long-term effects of CPAP upon neuropsychological function in patients with SAS, the current authors designed a prospective controlled study that evaluated the effects of 1 yr of treatment with CPAP upon cognitive performance, daytime sleepiness and mood in a large group (n=80) of such patients.

Material and methods

Population

Patients were recruited prospectively from all those attending the sleep unit of the Hospital Universitari Son Dureta from November 1995 until April 1997. The inclusion criteria were: 1) had more than 20 apnoeas-hypopnoeas per hour of sleep (recorded during a full, standard polysomnographic study (Ultrasom Nicolette; Madison, WI, USA)); 2) required treatment with nasal CPAP, according to the criteria proposed by the Spanish Society of Pulmonology and Thoracic Surgery. These criteria recommend active treatment with CPAP whenever the apnoea-hypopnoea index is >20 h⁻¹ and there are clear symptoms of the disease and/or the patient has cardiovascular disease [19]; 3) lived permanently in Mallorca, Spain (to facilitate follow-up); and 4) had >8 yrs of school education (to allow the performance of some of the psychological tests used in the study). Candidates were excluded if they were drug abusers, had a psychiatric disorder, were shift-workers, and/or had been previously diagnosed of epilepsy, narcolepsy and/or periodic leg movements disease. Eighty-nine potential candidates were screened and nine were excluded (three shift-workers, two psychiatric disorders, one epilepsy, one periodic leg movements disease, one nonpermanent resident in Mallorca, and one who refused to participate). Finally, 80 patients (78 males) were included in the study.

The control subjects were nonmedical workers or visitors to the Hospital Universitari Son Dureta referred by faculty members of the authors’ institution, not directly involved in the study; patient relatives were specifically excluded. Control subjects were individually matched with patients for age (±5 yrs) and sex. Their inclusion and

Long-term effects of CPAP on daytime functioning in patients with sleep apnoea syndrome


*Servei Pneumologia, Hospital Universitari Son Dureta, Palma de Mallorca, Spain. **Escola Interferència, Universitat Illes Balears, Palma de Mallorca, Spain.

Accepted after revision January 19 2000

Keywords: Continuous positive airway pressure, reaction time, sleep apnoea syndrome, sleepiness, vigilance

Supported, in part, by Direcció de Tràfic, Carburos Metàl·lics and Asociación Balear per L’Estudi de les Malalties Respiratories

exclusion criteria were the same as mentioned above for patients, except for the presence of SAS. This was excluded clinically [20] or, if necessary, after a full polysomnography. Eighty-two volunteers were screened, in whom three polysomnographic studies were required. SAS was diagnosed in two of these three individuals, who were accordingly excluded. Hence, a total of 80 healthy control subjects (78 males) were finally included in the study.

The protocol was approved by the Ethics Committee of the authors’ institution. All participants signed their written consent after being fully aware of the aims, nature and characteristics of the study.

Study design

In all participants (patients and control subjects), measurements were obtained at the beginning of the study and 12±1 months later. In patients, but not in control subjects, measurements were also obtained 3±0.1 months after the initiation of CPAP treatment.

Measurements

The authors used a standardized questionnaire to record data on occupation, previous medical conditions, use of drugs, number of hours of sleep per day, and alcohol and coffee intake. The degree of subjective sleepiness was measured with the Epworth scale [21] and the level of anxiety and depression with the Beck questionnaires [22]. Reaction time was explored using the Psychometer Vigilance Test (PVT 192®; CWE, Inc., Ardmore, PA, USA) [23]. This device incorporates a red light that flashes at random intervals during the test (~80–85 times in 10 min). Subjects were asked to press a button as soon as they realized that the red light has flashed. The period of time elapsed between these two events (reaction time) was recorded in a computer for later analysis, following the methodology previously reported in the authors’ laboratory [24]. The test was performed, between 10:00–12:00 h. The level of vigilance was investigated using the Steer-Clear® test (Findley & Fabricio, Charlottesville, VA, USA) [25], also between 10:00–12:00 h.

Briefly, for 30 min, subjects were asked to sit in front of a computer screen showing a small car running through a long, linear road. Unexpectedly, at random intervals, an object (steer) appeared in the road. The individual had to press the space bar to avoid hitting the steer. As previously reported [24], the test was set such that 500 steers appeared during the 30 min duration. The number of hits was recorded by the computer every minute. For each subject, data was later analysed and expressed both in absolute values (during the initial and final parts of the test) and also as the percentage of hits during the whole duration of the test. Compliance with CPAP was assessed with the time counter built up in each CPAP device (REMstar; Respironics, Monroeville, PA, USA).

Statistical analysis

Results are shown as mean±SEM. For discrete variables, differences between groups were investigated by the Chi-squared test. For continuous variables, the statistical significance of differences was first assessed using a two-way analysis of variance (ANOVA). If significant, a one-way ANOVA was then used to evaluate the effects of CPAP through time in patients, while a paired t-test was used to investigate potential changes in control subjects. Differences between groups at any given point in time were investigated using a t-test for independent samples. The significance of changes in psychosocial variables was also assessed by the calculation of the effect sizes [26].

An effect size of 0.2 is considered small, 0.5 medium and 0.8 large [17]. The association between CPAP compliance and the change with time of different variables of interest was explored using the Pearson correlation test. Statistical significance was accepted at p<0.05.

Results

Data at baseline

Table 1 shows the main anthropometric data of all participants at the beginning of the study. Patients were slightly but significantly older than control subjects. However, the difference was of marginal biological relevance. As expected, patients were more obese than control subjects (p<0.01). Also, both the systolic and diastolic blood pressure levels were higher (p<0.01) in patients. The severity of SAS in patients ranged from mild (21 apnoeas/hypopnoeas-h⁻¹) to severe (123 apnoeas-hypopnoeas-h⁻¹) with a mean apnoea-hypopnoea index of 60±2-h⁻¹. The lowest nocturnal oxygen saturation was 64±2%.

Table 2 presents the values of some potentially confounding variables recorded in patients and control subjects. The same number of individuals received treatment with b-blockers (three versus one) and, oral anti-diabetics (five versus three) in both groups, although benzodiazepines (eight versus two, p=0.05) and antidepresant drugs (five versus zero, p<0.05), were consumed more often in patients than in control subjects. Alcohol consumption was similar (and modest) in both groups (table 2), but patients consumed slightly higher quantities than control subjects during the weekend (p<0.05). Coffee intake and number of hours of reported sleep per day were similar in patients and control subjects (table 2).

Before CPAP patients were more depressed and anxious than control subjects (table 3, fig. 1). In absolute terms, though, these values are only moderately abnormal [22]. As expected, patients were more somnolent than healthy

<table>
<thead>
<tr>
<th>Table 1. – Anthropometric data of all participants at baseline</th>
<th>Patients</th>
<th>Control subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Age yrs</td>
<td>49±1</td>
<td>46±1*</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>78/2</td>
<td>78/2</td>
</tr>
<tr>
<td>Body mass index kg·m⁻²</td>
<td>33±1</td>
<td>26±0.4**</td>
</tr>
<tr>
<td>Systolic blood pressure mmHg</td>
<td>132±2</td>
<td>124±2**</td>
</tr>
<tr>
<td>Diastolic blood pressure mmHg</td>
<td>84±2</td>
<td>76±1**</td>
</tr>
</tbody>
</table>

Data are expressed as mean±SEM. M: male; F: female. *: p<0.05; **: p<0.01, compared to patients. 1 mmHg=0.133 kPa.
control subjects (table 3, fig. 1). Table 3 also shows that patients had higher reaction time values and performed poorer in the Steer-Clear® test (fig. 2).

Follow-up

Some patients and control subjects were lost during follow-up. After 3 months, the authors were able to evaluate 74 patients. At the end of the study (12±1 months) 71 patients and 63 control subjects could be investigated. The only reason for losing patients and control subjects for follow-up was their reluctance to continue in the study. In no case was follow-up lost due to a medical reason. The anthropometric characteristics and the severity of the disease in patients lost for follow-up was not different from those investigated during the rest of the study period.

At this point in time, differences in body mass index between patients and control subjects persisted unaltered with respect to the initiation of the study (32±0.6 versus 27±0.5 kg·m⁻², p<0.001). Three patients and two control subjects consumed benzodiazepines and four patients and one control subject consumed antidepressant drugs (p=NS). Alcohol and coffee intake did not change in any group during the course of the study. Finally, the number of hours of reported sleep per night remained unchanged (8±0.1 versus 8±0.3 h). On average, patients used CPAP for 678 A. MUNOZ ET AL. 0.4±10.95 h. None of these variables changed significantly with respect to the main neuropsychological variables assessed in the study. None of these variables changed very significantly while, interestingly, others did not. Depression and anxiety scores were amongst those variables not influenced by treatment (fig. 1). In contrast, the levels of somnolence (Epworth scale) and vigilance (Steer-Clear®) were significantly improved by CPAP (fig. 2a and c). Such an improvement was already evident after 3 months of treatment and tended to improve further after 12±1 months. The Epworth scale improved further (slightly but significantly) from month 3 to month 12 (from 5.8±0.2 to 4.3±0.4, p<0.05). Finally, differences in reaction time failed to reach statistical significance (two-way ANOVA), but values in patients tended to normalize with time and, the difference that was observed with the control group before treatment disappeared after CPAP (fig. 2b). Table 4 presents the analysis of the effect sizes. None of the

<table>
<thead>
<tr>
<th>n</th>
<th>80</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzodiazepine use</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Antidepressant use</td>
<td>5</td>
<td>0*</td>
</tr>
<tr>
<td>Alcohol consumption g·day⁻¹</td>
<td>15±3</td>
<td>11±2</td>
</tr>
<tr>
<td>Mean dose during the weekend</td>
<td>30±4</td>
<td>20±2*</td>
</tr>
<tr>
<td>Coffee intake cups·day⁻¹</td>
<td>2±0.2</td>
<td>2±0.2</td>
</tr>
<tr>
<td>Number of hours of sleep·day⁻¹</td>
<td>8±0.2</td>
<td>8±0.2</td>
</tr>
</tbody>
</table>

*: p<0.05 compared to patients.

Follow-up

Some patients and control subjects were lost during follow-up. After 3 months, the authors were able to evaluate 74 patients. At the end of the study (12±1 months) 71 patients and 63 control subjects could be investigated. The only reason for losing patients and control subjects for follow-up was their reluctance to continue in the study. In no case was follow-up lost due to a medical reason. The anthropometric characteristics and the severity of the disease in patients lost for follow-up was not different from those investigated during the rest of the study period.

At this point in time, differences in body mass index between patients and control subjects persisted unaltered with respect to the initiation of the study (32±0.6 versus 27±0.5 kg·m⁻², p<0.001). Three patients and two control subjects consumed benzodiazepines and four patients and one control subject consumed antidepressant drugs (p=NS). Alcohol and coffee intake did not change in any group during the course of the study. Finally, the number of hours of reported sleep per night remained unchanged (8±0.1 versus 8±0.3 h). On average, patients used CPAP for 5.8±0.2 h·night⁻¹, although individual compliance ranged 0.4–10.95 h.

Figures 1 and 2 present the evolution through time of the main neuropsychological variables assessed in the study. None of these variables changed significantly within the control group. This was not the case in patients with SAS, in whom some variables changed very significantly while, interestingly, others did not. Depression and anxiety scores were amongst those variables not influenced by treatment (fig. 1). In contrast, the levels of somnolence (Epworth scale) and vigilance (Steer-Clear®) were significantly improved by CPAP (fig. 2a and c). Such an improvement was already evident after 3 months of treatment and tended to improve further after 12±1 months. The Epworth scale improved further (slightly but significantly) from month 3 to month 12 (from 5.8±0.2 to 4.3±0.4, p<0.05). Finally, differences in reaction time failed to reach statistical significance (two-way ANOVA), but values in patients tended to normalize with time and, the difference that was observed with the control group before treatment disappeared after CPAP (fig. 2b). Table 4 presents the analysis of the effect sizes. None of the

| Reaction time ms | 280±5 | 264±4* |
| Patients | 80 | 80 |
| Control subjects |

Data are expressed as mean±SEM. *: p<0.05; **: p<0.01; ***: p<0.001, compared to patients.

Follow-up

Some patients and control subjects were lost during follow-up. After 3 months, the authors were able to evaluate 74 patients. At the end of the study (12±1 months) 71 patients and 63 control subjects could be investigated. The only reason for losing patients and control subjects for follow-up was their reluctance to continue in the study. In no case was follow-up lost due to a medical reason. The anthropometric characteristics and the severity of the disease in patients lost for follow-up was not different from those investigated during the rest of the study period.

At this point in time, differences in body mass index between patients and control subjects persisted unaltered with respect to the initiation of the study (32±0.6 versus 27±0.5 kg·m⁻², p<0.001). Three patients and two control subjects consumed benzodiazepines and four patients and one control subject consumed antidepressant drugs (p=NS). Alcohol and coffee intake did not change in any group during the course of the study. Finally, the number of hours of reported sleep per night remained unchanged (8±0.1 versus 8±0.3 h). On average, patients used CPAP for 5.8±0.2 h·night⁻¹, although individual compliance ranged 0.4–10.95 h.

Figures 1 and 2 present the evolution through time of the main neuropsychological variables assessed in the study. None of these variables changed significantly within the control group. This was not the case in patients with SAS, in whom some variables changed very significantly while, interestingly, others did not. Depression and anxiety scores were amongst those variables not influenced by treatment (fig. 1). In contrast, the levels of somnolence (Epworth scale) and vigilance (Steer-Clear®) were significantly improved by CPAP (fig. 2a and c). Such an improvement was already evident after 3 months of treatment and tended to improve further after 12±1 months. The Epworth scale improved further (slightly but significantly) from month 3 to month 12 (from 5.8±0.2 to 4.3±0.4, p<0.05). Finally, differences in reaction time failed to reach statistical significance (two-way ANOVA), but values in patients tended to normalize with time and, the difference that was observed with the control group before treatment disappeared after CPAP (fig. 2b). Table 4 presents the analysis of the effect sizes. None of the

| Reaction time ms | 280±5 | 264±4* |
| Patients | 80 | 80 |
| Control subjects |

Data are expressed as mean±SEM. *: p<0.05; **: p<0.01; ***: p<0.001, compared to patients.
Table 4. – Effect sizes of the observed changes at 12 months of follow-up in the two groups of subjects studied

<table>
<thead>
<tr>
<th></th>
<th>Patients</th>
<th>Control subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>( n )</td>
<td>72</td>
<td>63</td>
</tr>
<tr>
<td>Somnolence Epworth scale</td>
<td>3.76</td>
<td>0.16***</td>
</tr>
<tr>
<td>Depression score Beck test</td>
<td>0.19</td>
<td>0.02</td>
</tr>
<tr>
<td>Anxiety score Beck test</td>
<td>0.1</td>
<td>0.01</td>
</tr>
<tr>
<td>Steer-Clear ( \text{hit} % ) hits</td>
<td>1.57</td>
<td>-0.22***</td>
</tr>
<tr>
<td>Hits (0–15\text{-min}^{-1})</td>
<td>1.06</td>
<td>-0.012</td>
</tr>
<tr>
<td>Hits (15–30\text{-min}^{-1})</td>
<td>0.89</td>
<td>-0.25**</td>
</tr>
<tr>
<td>Reaction time (\text{ms})</td>
<td>0.27</td>
<td>-0.18</td>
</tr>
</tbody>
</table>

* \( p<0.05 \); ** \( p<0.01 \); *** \( p<0.001 \), compared to patients. \( z \): \( p=0.06 \).

Changes observed in the control group were greater than 0.2 (the minimum threshold value to consider it biologically relevant) [17]. In contrast, several of the variables show an effect size >0.8 in the patients with SAS, indicating a large biological effect [17]. Differences between groups reached statistical significance in these same variables (table 4).

Finally, the authors explored the relationship between the compliance with CPAP treatment and the changes observed in the above mentioned variables after 12±1 months on CPAP. It was found that the former was significantly related to the improvement of somnolence (fig. 3). Interestingly, changes in Steer-Clear \( \text{hit} \% \) performance were not related to the level of compliance with CPAP treatment. Also, the lack of changes in the remaining variables analysed in this study (depression, anxiety and reaction time) explains the absence of a significant relationship with CPAP compliance.

Discussion

The results of this large, long-term, prospective controlled study provide firm evidence to substantiate the use of CPAP in patients with SAS. Specifically, they show that the long-term use of CPAP significantly improves the levels of somnolence and vigilance, that these changes are already evident after 3 months of treatment, that they persist after 12±1 months on CPAP, and that they are not explained by the presence of some potentially confounding variables. Interestingly, however, they also show that the long-term use of CPAP does not normalize the levels of depression and anxiety seen in these patients.

The present study has several potential limitations that deserve comment. Firstly, it was not a randomized study. In theory, the ideal experimental design should probably have considered the randomization of patients with SAS to receive treatment with CPAP or placebo (sham CPAP) [27]. However, this was considered unethical because of the severity of the disease in the patients included (mean apnoea-hypopnoea index 60±2) and the duration of the study (1 yr follow-up). Secondly, the control group does not exclude a learning effect but cannot exclude a possible placebo effect. However, the correlation observed between the use of CPAP and the change in somnolence (dose/effect relationship; fig. 3) is an argument against the latter.

SAS is associated with a variety of neuropsychological effects [6, 7, 9, 13, 28–31]. The present study confirms that, before treatment, patients with SAS were more anxious, depressed and somnolent than matched healthy control subjects (table 3, figs. 1 and 2). Also, these patients had a higher reaction time and a lower level of vigilance (fig. 2). These latter observations confirm previous results from the authors’ laboratory [24]. It is widely accepted that CPAP treatment may be beneficial in patients with SAS for a variety of reasons [32]. Recently, however, some authors have claimed that the evidence sustaining these potentially beneficial effects of CPAP in SAS is weak [18]. Previous studies investigating the effects of CPAP on neuropsychological performance in SAS, were typically of short duration (weeks) and normally included only a small number of subjects [10–12, 14, 15]. With these limitations in mind, the results of these previous studies consistently show that CPAP improves sleepiness, vigilance, mental flexibility, attention, mood, functional status, general health and energy/fatigue in patients with mild, moderate and severe SAS [10–12, 14, 15, 17]. The results of the present study at 3 months (figs. 1 and 2) confirm these previous reports [33]. However, by including a larger population of patients (and a matched control group), as well as by following-up these individuals during a much longer period of time (12±1 months), the current findings strengthen the validity of these conclusions and extend them to a chronic situation. Accordingly, therefore, the results of this study provide firm evidence on which to substantiate the use of CPAP in patients with SAS. Furthermore, the analysis of the effect sizes of the observed changes (table 4) support this interpretation.

It was somewhat surprising to find out that CPAP did not improve the depression and anxiety scores, either at short or long-term (fig. 1). However, this observation is in keeping with a previous study assessing its effects in the short-term [12]. To explain these observations, several potential explanations can be considered. Low compliance with treatment can be excluded as a potential cause because, on average, this was quite acceptable (5.8±0.2 h-night\(^{-1}\)). It is possible that the questionnaires used in the study lacked discriminatory value to identify small differences after treatment. However, the authors think that this possibility is unlikely because of the magnitude of the...
observed differences (fig. 1). Alternatively, anxiety and depression in SAS may not be causally related to the number of apnoeas at night, which is the physiological event most dramatically improved by CPAP [34]. Yet, the observed correlation between CPAP compliance and somnolence improvement (fig. 3) also makes this possibility unlikely. It is possible that the chronic use of CPAP can generate anxiety and depression by itself. If so, this would counteract any potential improvement derived from the actual treatment of SAS. Finally, patients may remain anxious and depressed despite the use of CPAP because they are aware of the fact that this is a symptomatic, rather than curative, treatment. In any case, it should be remembered that the absolute level of depression and anxiety depicted by patients (fig. 1), although clearly different from control subjects is only mild to moderate in severity [22].

In summary, this study demonstrates that the use of continuous positive airway pressure in patients with sleep apnoea syndrome improves sleepiness and vigilance, both in the short and long-term. Continuous positive airway pressure does not improve the levels of anxiety or depression seen in these patients. Changes in reaction time were of small magnitude and of questionable clinical relevance.

Acknowledgements. The authors thank H. Engleman (University of Edinburgh, Scotland, UK) for statistical advice.

References
27. Farré R, Hernandez L, Montserrat JM, Rotger M, Baleste E, Navajas D. Sham continuous positive airway
pressure for placebo-controlled studies in sleep apnea. 


